| Cases | 
			Controls | 
			Cohort(Click to view selection criteria for cases and controls) | 
			Ancestry | 
		
|---|
| 782 | 
			2,785 | 
			Atherosclerosis Risk in Communities Study VTE cohort (ARIC)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c < 5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Mixed | 
		
| 27 | 
			863 | 
			Genetics of Cardiometabolic Health in the Amish (Amish)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c < 5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 14 | 
			293 | 
			Cleveland Clinic Atrial Fibrillation Study (CCAF)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 173 | 
			491 | 
			Cleveland Clinic Atrial Fibrillation Study (CFS)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Mixed | 
		
| 15 | 
			52 | 
			Cardiovascular Health Study (CHS)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 1,117 | 
			7,500 | 
			Genetic Epidemiology of COPD (COPDGene) in the TOPMed Program
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Mixed | 
		
| 293 | 
			18 | 
			Diabetes Heart Study (DHS)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Mixed | 
		
| 620 | 
			3,001 | 
			Framingham Heart Study (FHS)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 350 | 
			642 | 
			Genetic Epidemiology Network of Arteriopathy (GENOA)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			African | 
		
| 59 | 
			708 | 
			Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 138 | 
			1,461 | 
			Genetic Epidemiology Network of Salt Sensitivity (GenSALT)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Asian | 
		
| 198 | 
			1,351 | 
			Genetic Studies of Atherosclerosis Risk (GeneSTAR)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Mixed | 
		
| 4 | 
			59 | 
			Heart and Vascular Health Study (HVH)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 323 | 
			1,329 | 
			Hypertension Genetic Epidemiology Network (HyperGEN)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			African | 
		
| 1,034 | 
			2,076 | 
			Jackson Heart Study (JHS)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			African | 
		
| 1,022 | 
			3,766 | 
			Multi-Ethnic Study of Atherosclerosis (MESA)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Mixed | 
		
| 52 | 
			830 | 
			Massachusetts General Hospital Atrial Fibrillation Study (MGH_AF)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 16 | 
			88 | 
			Partners Healthcare Biorepository (Partners)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 232 | 
			781 | 
			Whole Genome Sequencing to Identify Causal Genetic Variants Influencing CVD Risk - San Antonio Family Studies (SAFS)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Hispanic | 
		
| 185 | 
			918 | 
			Samoan Adiposity Study (Samoan)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Samoan | 
		
| 26 | 
			128 | 
			Vanderbilt Atrial Fibrillation Ablation Registry (VAFAR)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 172 | 
			812 | 
			Vanderbilt Genetic Basis of Atrial Fibrillation (VU_AF)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			European | 
		
| 2,787 | 
			5,041 | 
			Women's Health Initiative (WHI)
			
			| Case selection criteria | 
						Control selection criteria | 
					
|---|
 | Fasting glucose ≥ 7 mmol/L OR treatment OR HbA1c ≥ 6.5% OR 2-hr OGTT ≥11.1 mmol/L, OR random/non-fasting glucose ≥ 11.1 mmol/L OR physician diagnosis OR self-reported diabetes | 
						Fasting glucose < 5.6 mmol/L, AND HbA1c <5.7% (if available), AND 2-hr OGTT < 7.8 mmol/L (if available), AND Not on diabetes medication | 
					 
  
			 | 
			Mixed |